Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | SCN4A | P35499 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NSD1 | Q96L73 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492745 | 0.81 | RAB9A (0.37) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21160893 | 0.81 | RAB9A (0.36) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20666431 | 0.80 | ALDH1A1 (0.62) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21161373 | 0.78 | RAB9A (0.33) | ALDH1A1SMN1; SMN2RAB9ANPC1SCN4A | |
| SCHEMBL14044812 | 0.77 | HSD17B10 (0.68) | ALDH1A1LMNASMN1; SMN2RAB9AHSD17B10 | |
| SCHEMBL474219 | 0.77 | ALDH1A1 (0.61) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL27051852 | 0.77 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13486437 | 0.76 | ALDH1A1 (0.49) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL27051717 | 0.75 | ALDH1A1 (0.65) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL27051858 | 0.74 | ALDH1A1 (0.54) | ALDH1A1LMNASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 4376/4885LMNA 2106/4885SMN1; SMN2 3668/4885 |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | ALDH1A1 1686/4885LMNA 2322/4885SMN1; SMN2 713/4885 |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 4376/4885LMNA 2106/4885SMN1; SMN2 3668/4885 |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 4376/4885LMNA 2106/4885SMN1; SMN2 3668/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | ALDH1A1 1686/4885LMNA 2322/4885SMN1; SMN2 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.